WO2001080890A3 - Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype - Google Patents

Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype Download PDF

Info

Publication number
WO2001080890A3
WO2001080890A3 PCT/CA2001/000566 CA0100566W WO0180890A3 WO 2001080890 A3 WO2001080890 A3 WO 2001080890A3 CA 0100566 W CA0100566 W CA 0100566W WO 0180890 A3 WO0180890 A3 WO 0180890A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulations
methods
nitric oxide
cell phenotype
malignant cell
Prior art date
Application number
PCT/CA2001/000566
Other languages
French (fr)
Other versions
WO2001080890A2 (en
Inventor
Michael A Adams
Charles H Graham
Jeremy P W Heaton
Lynne-Marie Postovit
Original Assignee
Univ Kingston
Michael A Adams
Charles H Graham
Jeremy P W Heaton
Lynne-Marie Postovit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2407466A priority Critical patent/CA2407466C/en
Application filed by Univ Kingston, Michael A Adams, Charles H Graham, Jeremy P W Heaton, Lynne-Marie Postovit filed Critical Univ Kingston
Priority to DE60106905T priority patent/DE60106905T2/en
Priority to EP01923448A priority patent/EP1278547B1/en
Priority to AU5022101A priority patent/AU5022101A/en
Priority to AU2001250221A priority patent/AU2001250221B2/en
Priority to AT01923448T priority patent/ATE281177T1/en
Priority to IL15242801A priority patent/IL152428A0/en
Priority to MXPA02010551A priority patent/MXPA02010551A/en
Priority to JP2001577987A priority patent/JP2003531179A/en
Publication of WO2001080890A2 publication Critical patent/WO2001080890A2/en
Publication of WO2001080890A3 publication Critical patent/WO2001080890A3/en
Priority to IL152428A priority patent/IL152428A/en
Priority to HK03104814.3A priority patent/HK1052468B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Abstract

Methods and formulations for inhibiting and preventing a malignant cell phenotype by administering to cells a low dose of a nitric oxide mimetic are provided.
PCT/CA2001/000566 2000-04-26 2001-04-26 Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype WO2001080890A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
AT01923448T ATE281177T1 (en) 2000-04-26 2001-04-26 FORMULATIONS AND METHODS FOR USING NITROGEN MONOXIDE MIMETICS AGAINST A MALIGNANT CELL PHENOTYPE
DE60106905T DE60106905T2 (en) 2000-04-26 2001-04-26 FORMULATIONS AND METHOD FOR THE USE OF NITROGEN MONEY MIMETICS TO A MALIGNING CELL PHENOTYPE
EP01923448A EP1278547B1 (en) 2000-04-26 2001-04-26 Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
AU5022101A AU5022101A (en) 2000-04-26 2001-04-26 Formulations and methods of using nitric oxide mimetics against a malignant cellphenotype
AU2001250221A AU2001250221B2 (en) 2000-04-26 2001-04-26 Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
CA2407466A CA2407466C (en) 2000-04-26 2001-04-26 Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
IL15242801A IL152428A0 (en) 2000-04-26 2001-04-26 Formulations and method of using nitric oxide mimetics against a malignant cell phenotype
MXPA02010551A MXPA02010551A (en) 2000-04-26 2001-04-26 Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype.
JP2001577987A JP2003531179A (en) 2000-04-26 2001-04-26 Formulations and methods of using nitric oxide mimetics for malignant cell phenotype
IL152428A IL152428A (en) 2000-04-26 2002-10-22 Nitric oxide mimetic compositions for use against a malignant cell phenotype
HK03104814.3A HK1052468B (en) 2000-04-26 2003-07-07 Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19975700P 2000-04-26 2000-04-26
US60/199,757 2000-04-26
US27746901P 2001-03-21 2001-03-21
US60/277,469 2001-03-21

Publications (2)

Publication Number Publication Date
WO2001080890A2 WO2001080890A2 (en) 2001-11-01
WO2001080890A3 true WO2001080890A3 (en) 2002-08-08

Family

ID=26895114

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2001/000566 WO2001080890A2 (en) 2000-04-26 2001-04-26 Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype

Country Status (12)

Country Link
US (1) US6946484B2 (en)
EP (1) EP1278547B1 (en)
JP (1) JP2003531179A (en)
AT (1) ATE281177T1 (en)
AU (2) AU2001250221B2 (en)
CA (1) CA2407466C (en)
DE (1) DE60106905T2 (en)
ES (1) ES2232613T3 (en)
HK (1) HK1052468B (en)
IL (2) IL152428A0 (en)
MX (1) MXPA02010551A (en)
WO (1) WO2001080890A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8927030B2 (en) 2003-07-09 2015-01-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678391B2 (en) 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
GB0125222D0 (en) * 2001-10-19 2001-12-12 Barts & London Nhs Trust Composition for the treatment of microbial infections
JP2005527510A (en) * 2002-03-06 2005-09-15 セレジー ファーマシューティカルズ インコーポレーティッド Formulations and methods for using nitric oxide mimetics in the treatment of cancer
US20050119278A1 (en) * 2002-05-16 2005-06-02 Che-Ming Teng Anti-angiogenesis methods
US20050096370A1 (en) * 2003-04-07 2005-05-05 Bizbiotech Co., Ltd. Method for inhibiting tumor angiogenesis and tumor growth
DK2348114T3 (en) 2004-04-21 2018-09-03 Alexion Pharma Inc BONE DELIVERY CONJUGATES AND PROCEDURE TO USE IT FOR TARGETING PROTEINS AGAINST BONE
SE0401871D0 (en) * 2004-07-15 2004-07-15 Glucogene Medical Hfm Ab New compositions
AU2005289756B2 (en) * 2004-09-22 2011-10-13 Tripath Imaging, Inc. Methods and computer program products for analysis and optimization of marker candidates for cancer prognosis
US8557300B2 (en) 2005-05-19 2013-10-15 University Of Cincinnati Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
JP5274248B2 (en) 2005-05-27 2013-08-28 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル Nitric oxide releasing particles for nitric oxide therapy and biomedical applications
US20070172847A1 (en) * 2005-11-15 2007-07-26 The Regents Of The University Of California Molecular signaling pathways triggered by rituximab: prognostic, diagnostic, and therapeutic uses
US20070202155A1 (en) * 2006-02-03 2007-08-30 Cure Therapeutics, Inc. Low dose no donor-containing transdermal patch
US8968702B2 (en) 2006-03-30 2015-03-03 Duke University Inhibition of HIF-1 activation for anti-tumor and anti-inflammatory responses
GB0607402D0 (en) 2006-04-12 2006-05-24 Barts & London Nhs Trust Therapeutic composition and use
US20070259026A1 (en) * 2006-04-20 2007-11-08 Robert Ang Vasodialating dressing for use with intravenous catheters
WO2010037095A2 (en) * 2008-09-29 2010-04-01 Nometics Agents and methods for the treatment of cancer
WO2010114602A1 (en) * 2009-03-31 2010-10-07 Sand9, Inc. Integration of piezoelectric materials with substrates
CN102695528B (en) 2009-08-21 2016-07-13 诺万公司 Wound dressing, its using method and forming method thereof
CA3062005C (en) 2009-08-21 2022-02-15 Novan, Inc. Topical gels comprising nitric oxide-releasing polysiloxane macromolecules and uses thereof
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
US9266939B2 (en) 2010-12-27 2016-02-23 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
US20140072557A1 (en) * 2011-02-28 2014-03-13 National Cerebral And Cardiovascular Center Medicinal agent for suppressing malignant tumor metastasis
ES2695173T3 (en) 2011-02-28 2019-01-02 Novan Inc Silica particles modified with S-nitrosothiol that release nitric oxide and methods of manufacturing them
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
USD949597S1 (en) 2014-06-15 2022-04-26 Bengt Johansson Flooring guard for pets
USD974802S1 (en) * 2013-06-16 2023-01-10 Bengt Johansson Flooring guard for pets
USD975470S1 (en) * 2014-06-15 2023-01-17 Bengt Johansson Flooring guard for pets
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
WO2016015095A1 (en) * 2014-07-31 2016-02-04 The University Of Western Australia A method for the identification of immunotherapy-drug combinations using a network approach
JP6764864B2 (en) * 2014-08-08 2020-10-07 ポセイダ セラピューティクス， インコーポレイテッド Compositions and Methods for Inducing Nanoparticle-Mediated Microvascular Embolus Formation in Tumors
WO2016090251A1 (en) 2014-12-05 2016-06-09 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
US10456452B2 (en) 2015-07-02 2019-10-29 Poseida Therapeutics, Inc. Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles
RU2745528C2 (en) 2015-08-17 2021-03-26 Алексион Фармасьютикалз, Инк. Production of alkaline phosphatases
US11229686B2 (en) 2015-09-28 2022-01-25 Alexion Pharmaceuticals, Inc. Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
EP3426286A4 (en) 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
CA3019726A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
ES2865481T3 (en) 2016-04-29 2021-10-15 Poseida Therapeutics Inc Poly (histidine) -based micelles for complexation and delivery of proteins and nucleic acids
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
JP7018933B2 (en) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド How to treat bronchomalacia
AU2018243320A1 (en) 2017-03-31 2019-10-10 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (HPP) in adults and adolescents
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
CN113975264A (en) * 2018-04-16 2022-01-28 上海岸阔医药科技有限公司 Method for preventing or treating side effects of tumor therapy

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5434256A (en) 1988-11-22 1995-07-18 Board Of Regents, The University Of Texas System Diamine platinum complexes as antitumor agents
US5840759A (en) * 1993-10-08 1998-11-24 The United States Of America As Represented By The Department Of Health And Human Services Use of nitric oxide releasing compounds to protect noncancerous cells from chemotherapeutic agents
DE69425331D1 (en) * 1993-10-08 2000-08-24 Us Health USE OF NITROGEN OXID RELEASING COMPOUNDS AS A MEDICINE FOR RADIATION SENSITIZATION FOR HYPOXIC CELLS
US5700830A (en) * 1994-11-22 1997-12-23 The United States Of America As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents for reducing metastasis risk
LV11542B (en) 1995-03-30 1997-02-20 Latvijas Organiskas Sintezes Instituts Substituted 1,3,9,11-tetraoxa-4,5,7,8-tetraazaundecadien-4,7-dioxides-5,7, preparation and use thereof
US6153186A (en) 1995-09-15 2000-11-28 Duke University Medical Center Red blood cells loaded with S-nitrosothiol and uses therefor
US5849790A (en) 1995-11-17 1998-12-15 The University Of South Florida (Mono) ethylenediaminenitroplatinum (IV) complexes with ligands of oxides of nitrogen as possible anti-tumor agents
DE19732323C2 (en) * 1996-08-06 1999-08-19 Dunzendorfer Drug combination for increased drug concentration in tissues
US6057367A (en) 1996-08-30 2000-05-02 Duke University Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
CA2705474C (en) 1996-09-27 2013-07-16 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services O2-glycosylated 1-substituted diazen-1-ium-1,2-diolates
WO1999003462A1 (en) 1997-07-14 1999-01-28 Brigham And Women's Hospital Modification of nitric oxide activity to treat fas-induced pathologies
ATE277038T1 (en) 1997-12-23 2004-10-15 Amersham Health As NITROGEN OXIDE RELEASING CHELATING AGENTS AND THEIR THERAPEUTIC USE
WO1999057306A2 (en) 1998-05-01 1999-11-11 Queen's University At Kingston Method for diagnosing a vascular condition
US6103275A (en) 1998-06-10 2000-08-15 Nitric Oxide Solutions Systems and methods for topical treatment with nitric oxide
US6235782B1 (en) 1998-11-12 2001-05-22 Rifat Pamukcu Method for treating a patient with neoplasia by treatment with a platinum coordination complex
AU2900100A (en) 1999-03-05 2000-09-21 Merck Frosst Canada & Co. Methods for inhibiting cathepsin k activity for the treatment of diseases related to bone loss
US6171620B1 (en) 1999-04-27 2001-01-09 Health Research, Inc. Method of enhancing the efficacy of anti-tumor agents
EP1251840A2 (en) 2000-01-26 2002-10-30 Cedars-Sinai Medical Center Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor
SE0000303D0 (en) * 2000-01-31 2000-01-31 Xylogen Ab Novel compounds
AU4757901A (en) 2000-03-20 2001-10-03 Novovascular Inc Matrices containing nitric oxide donors and reducing agents and their use
US20010038832A1 (en) 2000-04-11 2001-11-08 Benjamin Bonavida Nitric oxide and analogues thereof effectuate sensitization of neoplasm and immunologically undesired tissues to cytotoxicity
US7678391B2 (en) * 2000-04-26 2010-03-16 Queen's University At Kingston Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
US6270779B1 (en) 2000-05-10 2001-08-07 United States Of America Nitric oxide-releasing metallic medical devices
CA2410632A1 (en) 2000-06-22 2001-12-27 David S. Garvey Nitrosated and nitrosylated taxanes, compositions and methods of use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
K.A.DOOKERAN: "Mechanisms of antitumor activity for sustained-release nitric-oxide donor, nitroprusside in ethiodol", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 41, 2000, pages 280, XP001064169 *
K.SUMITANI E.A.: "Cytotoxic effect of sodium nitroprusside on cancer cells: involvement of apoptosis and suppression of C-MYC and C-MYB proto-oncogene expression", ANTICANCER RESEARCH, vol. 17, no. 2A, 1997, pages 865 - 871, XP001064190 *
V.UMANSKY E.A.: "Activated endothelial cells induce apoptosis in lymphoma cells: role of nitric oxide", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 10, no. 3, 1997, pages 465 - 471, XP001064191 *
V.UMANSKY E.A.: "Nitric oxide-mediated apoptosis in human breast cancer cells requires changes in mitochondrial functions and is independent of CD95 (APO-1/Fas)", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 16, no. 1, 2000, pages 109 - 117, XP001064253 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8927030B2 (en) 2003-07-09 2015-01-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of nitrite salts for the treatment of cardiovascular conditions
US9387224B2 (en) 2003-07-09 2016-07-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatment of specific cardiovascular conditions with nitrite

Also Published As

Publication number Publication date
HK1052468B (en) 2005-06-03
HK1052468A1 (en) 2003-09-19
AU2001250221B2 (en) 2006-07-06
WO2001080890A2 (en) 2001-11-01
ATE281177T1 (en) 2004-11-15
DE60106905T2 (en) 2005-12-01
CA2407466C (en) 2010-11-02
ES2232613T3 (en) 2005-06-01
AU5022101A (en) 2001-11-07
IL152428A0 (en) 2003-05-29
EP1278547A2 (en) 2003-01-29
DE60106905D1 (en) 2004-12-09
IL152428A (en) 2011-06-30
EP1278547B1 (en) 2004-11-03
US6946484B2 (en) 2005-09-20
MXPA02010551A (en) 2003-09-25
JP2003531179A (en) 2003-10-21
US20020040059A1 (en) 2002-04-04
CA2407466A1 (en) 2001-11-01

Similar Documents

Publication Publication Date Title
WO2001080890A3 (en) Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
WO2001054679A3 (en) Transdermal composition containing an anesthetic and a vasodilator agent
AU2001257326A1 (en) Topical anesthetic/opioid formulations and uses thereof
MY135721A (en) Amidino compounds useful as nitric oxide synthase inhibitors
AU2530801A (en) Improvements in and relating to nuclear fuel assemblies
WO2001024816A3 (en) Compositions and methods relating to the inhibition of casomorphin and gluteomorphin
AU2002359270A1 (en) Improved solid oxide fuel cells and interconnectors
WO2003049680A3 (en) Compositions containing both sedative and non-sedative antihistamines
IL156399A0 (en) Protection, restoration, and enhancement of erythropoietein-responsive cells, tissues and organs
AU2002227910A1 (en) Novel medicament compositions based on tiotropium salts and on salmeterol salts
AU2003215311A8 (en) Solid oxide fuel cell and system
HK1073075A1 (en) Use of an opuntia ficus-indica extract and compounds isolated therefrom for the preparation of the medicament for protecting nerve cells
AU3960400A (en) Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv
AU5331300A (en) Prophylactic, therapeutic and industrial antioxidant compositions enhanced with stabilized atomic hydrogen/free electrons and methods to prepare and use such compositions
GEP20043383B (en) Cell Adhesion-Inhibiting Antiinflammatory and Immune-Suppressive Compounds
AU2001274378A1 (en) Nuclear reactor of the pebble bed type
AU2001269688A1 (en) Combination containing an antifolate and methylmalonic acid lowering agent
MXPA03002207A (en) 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors.
AU2001295850A1 (en) Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
MXPA03004209A (en) Pharmaceutical or cosmetic composition and use of a pkc inhibitor with an mmp inhibitor for inhibiting langerhans cell migration.
SG149053A1 (en) Hippophae rhamnoides compositions for cancer therapy
EP1538162A3 (en) Compositions for altering mucus secretion
AU4474401A (en) Fuel for use in fuel cell
WO2002032447A3 (en) Cell damage inhibitor
HK1045813B (en) Non-solid composition for local application comprising glycerol and alchemilla vulgaris extract

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 152428

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/010551

Country of ref document: MX

Ref document number: 2407466

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2001 577987

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001250221

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2001923448

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001923448

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2001923448

Country of ref document: EP